Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Rotavirus Infections Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Rotavirus Infections Overview | 8 | 1 |
| Pipeline Products for Rotavirus Infections Comparative Analysis | 9 | 1 |
| Rotavirus Infections Therapeutics under Development by Companies | 10 | 1 |
| Rotavirus Infections Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Rotavirus Infections Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Rotavirus Infections Products under Development by Companies | 15 | 1 |
| Rotavirus Infections Products under Investigation by Universities/Institutes | 16 | 1 |
| Rotavirus Infections Companies Involved in Therapeutics Development | 17 | 12 |
| Beijing Minhai Biotechnology Co., Ltd | 17 | 1 |
| Bharat Biotech International Limited | 18 | 1 |
| Biological E. Limited | 19 | 1 |
| Curevac AG | 20 | 1 |
| Medicago Inc. | 21 | 1 |
| MSD Wellcome Trust Hilleman Laboratories Pvt Ltd | 22 | 1 |
| Nanotherapeutics, Inc. | 23 | 1 |
| Serum Institute of India Limited | 24 | 1 |
| Shantha Biotechnics Limited | 25 | 1 |
| Sinovac Biotech Ltd. | 26 | 1 |
| Takeda Pharmaceutical Company Limited | 27 | 1 |
| Wuhan Institute of Biological Products Co., Ltd. | 28 | 1 |
| Rotavirus Infections Therapeutics Assessment | 29 | 7 |
| Assessment by Monotherapy Products | 29 | 1 |
| Assessment by Target | 30 | 2 |
| Assessment by Route of Administration | 32 | 2 |
| Assessment by Molecule Type | 34 | 2 |
| Drug Profiles | 36 | 19 |
| Rotavac-5C Drug Profile | 36 | 1 |
| rotavirus (pentavalent) vaccine Drug Profile | 37 | 1 |
| rotavirus (tetravalent) vaccine Drug Profile | 38 | 1 |
| Rotavirus (virus like particle) vaccine Drug Profile | 39 | 1 |
| rotavirus (virus like particle) vaccine Drug Profile | 40 | 1 |
| rotavirus (virus like particle) vaccine Drug Profile | 41 | 1 |
| rotavirus [Serotype P2-VP8] (monovalent) vaccine Drug Profile | 42 | 1 |
| rotavirus [Serotype P2] (trivalent) vaccine Drug Profile | 43 | 1 |
| Rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine Drug Profile | 44 | 1 |
| rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine Drug Profile | 45 | 1 |
| Rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine Drug Profile | 46 | 2 |
| Rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine Drug Profile | 48 | 1 |
| Rotavirus [serotypes G1, G2, G3, G4] (tetravalent) vaccine Drug Profile | 49 | 1 |
| rotavirus vaccine Drug Profile | 50 | 1 |
| rotavirus vaccine Drug Profile | 51 | 1 |
| rotavirus vaccine Drug Profile | 52 | 1 |
| RV-3BB Drug Profile | 53 | 1 |
| RV-625 Drug Profile | 54 | 1 |
| Rotavirus Infections Dormant Projects | 55 | 1 |
| Rotavirus Infections Product Development Milestones | 56 | 5 |
| Featured News &Press Releases | 56 | 1 |
| Sep 21, 2016: Batavia Biosciences receives grant to develop new vaccine against rotavirus | 56 | 1 |
| Oct 14, 2014: Shantha`s Investigational Rotavirus Vaccine Enters Phase III Clinical Trials in India | 56 | 1 |
| Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate | 57 | 1 |
| Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus | 57 | 1 |
| Apr 26, 2012: GSK s Rotarix to Be Introduced in Ghana | 58 | 1 |
| Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan | 58 | 1 |
| May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix | 59 | 2 |
| Appendix | 61 | 2 |
| Methodology | 61 | 1 |
| Coverage | 61 | 1 |
| Secondary Research | 61 | 1 |
| Primary Research | 61 | 1 |
| Expert Panel Validation | 61 | 1 |
| Contact Us | 61 | 1 |
| Disclaimer | 62 | 1 |